Karen E. Knudsen was named CEO of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network.

City of Hope has received a $50 million gift for a 190,000-square-foot outpatient center in Irvine, Calif.As a result of the gift, from Lennar Foundation, an offshoot of a building company, the facility, which is slated to be opened in 2022, will be named Lennar Foundation Cancer Center at City of Hope Orange County. 

We are shocked and horrified by the recent spate of violence and hate crimes against people of Asian and Pacific Islander  descent across the United States.In response to these events, The Cancer Letter is stepping up coverage of inequities and disparities—and we are seeking your help and guidance on an upcoming series of investigative stories.As a publication that actively advocates for racial justice and health equity, we condemn these attacks, which have led to deaths, severe injuries, and widespread fear in AAPI communities.

José Baselga, an expert in the development of molecular targeted agents and an executive at AstraZeneca, died of Creutzfeldt-Jakob, an extremely rare, rapidly progressing, degenerative brain disorder.

In 1995, a group of doctors who advocated treating breast cancer with high dose chemotherapy with bone marrow transplantation made an attempt to include that highly toxic procedure in the guidelines of the nascent National Comprehensive Cancer Network.

An ad hoc group formed by NCI to provide advice on the slowly-accruing TMIST—Tomosynthesis Mammographic Imaging Screening Trial—recommended that the trial be streamlined, but should continue.

Late in 1997, when Bruce Ross told me that Bill McGivney would replace him as CEO of the National Comprehensive Cancer Network, I thought the recruitment made sense.

FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.

The National Comprehensive Cancer Network, an organization that promulgates guidelines based on standards of care provided at academic institutions in the U.S., is indisputably one of the pillars of oncology today.

Last year, Fox Chase Cancer Center stood poised to make history by becoming the first NCI-designated cancer center to be sold on open market.

Over the past three months, three pharmaceutical companies voluntarily withdrew three cancer indications for drugs that had previously received accelerated approvals from FDA, but ultimately failed to meet agreed-upon endpoints in confirmatory trials required for regular approvals.

A quarter century ago, on March 3, 1996, in Ft. Lauderdale, the National Comprehensive Cancer Network held a conference—its first.

Five academic cancer centers have formed a unique research alliance, Break Through Cancer, to focus on four cancer types—pancreatic cancer, ovarian cancer, glioblastoma, and acute myelogenous leukemia.

In a unanimous vote, the FDA Oncologic Drugs Advisory Committee recommended against an accelerated approval for Keytruda for patients with high-risk, early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then as a single agent as adjuvant treatment after surgery.

J enjoyed explaining that the letter J in his name appeared in his birth certificate.

Here is his bookJoseph V. Simone, medical director of St. Jude from 1983 to 1992, in the hospital's atrium.

In his previous job, in North Carolina, Edward S. Kim helped build a cancer program where there was none.

Walter J. (Wally) Curran, Jr., has stepped down from his positions as NRG Oncology presiding group chair and as one of the three principal investigators of the NRG Oncology.

On Jan. 20, as required, Ned Sharpless submitted his resignation letter to the outgoing administration. Other Trump appointees did the same.

The Cancer History Project finds and publishes Zubrod's autobiographyIn histories of oncology, Charles Gordon Zubrod is a name that flashes by quickly, someone who did something important a long time ago.

Mace Rothenberg has stepped down as chief medical officer at Pfizer. His successor is Aida Habtezion, a Stanford researcher whose work is focused on leukocyte recruitment and immune responses in diseases affecting the digestive organs.

Historical documents have a way of vanishing. Manuscripts, letters, and photographs end up in city dumps. Memories become less granular, insight is lost. The documents that do get preserved often require a trip to the archives.

Pharmaceutical and biotechnology industry groups, joined by cancer groups, filed legal challenges to an HHS rule that uses international reference prices to lower Medicare Part B prices.

On the way out, the Trump administration has finalized a rule that uses international reference prices to lower Medicare Part B prices.

Julie R. Gralow, an expert in breast cancer, clinical trials and global health, was named chief medical officer of the American Society of Clinical Oncology.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage is available here.

Will an oncologist of the not-so-distant future be able to pull up an image of a tumor biopsy slide on a screen and—without having to order a biomarker test—see the molecular characteristics of the cancer?

When he reported to work as director of Albert Einstein Cancer Center earlier this month, Edward Chu assumed responsibilities that are significantly broader and more comprehensive in scope than those of his predecessor, I. David Goldman.

A cancer pioneer, Helene G. Brown had coined the name for her peculiar subspecialty: political oncology.

Vincent P. Vinciguerra, the principal investigator of the Northwell Health NCI Community Oncology Research Program, won the 2020 Harry Hynes Award.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage is available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage is available here.

NCI's cancer screening trials may be falling victim to the COVID-19 pandemic.

NCI's publicly announced move to create an ad hoc working group that would review the feasibility and viability of the TMIST trial threatens to undercut this trial, said Mitchell Schnall, co-chair of ECOG-ACRIN Cancer Research Group, the group conducting the study.

Budget increases in 2020 enabled NCI to boost funding for research project grants, pushing the payline up by two percentage points from last year's level.

Gary Reedy announced that he will retire from his job as CEO of the American Cancer Society when his contract expires next April.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage is available here.

Raymond N. DuBois was named director of MUSC Hollings Cancer Center effective Aug. 17.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage is available here.

In the afternoon of July 22, the American Cancer Society instructed the staff of its National Home Office to pick up their belongings and equipment before July 30.

The FDA Oncologic Drugs Advisory Committee July 14 voted 12-0 to recommend approval for belantamab mafodotin for relapsed or refractory multiple myeloma.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. Our full coverage of SARS-CoV2 is available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. Our full coverage of SARS-CoV2 is available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. Our full coverage of SARS-CoV2 is available here.

By Paul Goldberg

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

It is not a matter of editorial opinion to say these words: Black Lives Matter.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

Deal becomes a “casualty of COVID-19”This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

FDA issues Emergency Use AuthorizationCredit: Sundry Photography / Shutterstock.com

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full directory of our coverage is available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our stories, as well as the latest meeting cancellations, are available here.

This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.

The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.

This story begins our occasional series looking back at the history of oncology since the signing of the National Cancer Act of 1971. The Cancer Letter was founded in 1973.

Explaining his decision to grant clemency to the financier Michael Milken, President Trump spoke thus:

In what appears to be a significant reorganization, Gary Reedy, CEO of the American Cancer Society, announced to the staff of the Atlanta-based charity that he will be stepping away from its day-to-day operations.

On Feb. 1, Thomas J. Lynch will report to work as president and director of Fred Hutchinson Cancer Research Center.

Richard Turman was named president on ACT for NIH, a Washington group that has played a key role in increasing federal appropriations for biomedical research over the past six years.

Consider these data points on cancer disparities:

The FDA Oncologic Drugs Advisory Committee in a session Dec. 17 and 18 considered three applications that were arranged thematically, to show how the agency is approaching indications where the number of patients is small and the disease catastrophic.

Stephen A. Chagares, a New Jersey general surgeon who recently set off a national debate by using a robotic surgical device to perform mastectomies, has filed a lawsuit claiming defamation and violation of federal and state antitrust laws on the part of Monmouth Medical Center.

As one of the cancer hospitals serving Los Angeles County, the UCLA Jonsson Comprehensive Center has to face the challenge of providing the most sophisticated—and most expensive—care to a largely underserved population.

David H. Thompson, a professor at the Department of Chemistry at Purdue University and a member of the Purdue Center for Cancer Research, is working on a better and faster way to produce drugs and eliminate shortages.

Lomustine, a.k.a. CCNU, is an old cancer drug.

The midterm elections of 1994 brought on political change that cost Dingell chairmanship of Energy & Commerce and Oversight and Investigations. He lost most of his staff, and there was no reason to continue oversight hearings of NSABP.

Bernard Fisher had been in many a fight. He was, after all, an iconoclastic surgeon who had famously infuriated his colleagues by demonstrating that heroic surgeries in breast cancer do more harm than good.

Bernard Fisher, a surgeon and clinical trialist who revolutionized the field of breast cancer research and all but eliminated reliance on disfiguring surgeries, died Oct. 16 at the age of 101.

The Trump administration has taken an important step toward nominating MD Anderson Cancer Center executive Stephen M. Hahn to the job of FDA commissioner, sources said.

In the first regulatory action of its kind, FDA and drug approval authorities in Canada and Australia simultaneously approved a new treatment for patients with endometrial carcinoma.

D. Gary Gilliland, president and director of Fred Hutchinson Cancer Research Center, plans to step down in 2020, the cancer center announced Sept. 17.

Philip J. Stella, the principal investigator of the Michigan Cancer Research Consortium NCI Community Oncology Research Program site in Ann Arbor, won the 2019 Harry Hynes Award.

The game of musical chairs involving topmost jobs in oncology has gathered speed and expanded beyond FDA and NCI, pulling in premier positions at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.

After six years of aggressively recruiting and spending more than $250 million to build up its programs, Sylvester Comprehensive Cancer Center has become the 71st NCI-designated cancer center in the US and the only such institution in South Florida.

Amarinthia Curtis has a community doctor's perspective on the scientific questions the Tomosynthesis Mammographic Imaging Screening Trial seeks to address.

The Wistar Institute Cancer Center and Christiana Care Health System's Helen F. Graham Cancer Center & Research Institute started a formal collaboration a decade ago.

The relationship between The Wistar Institute Cancer Center and Christiana Care's Helen F. Graham Cancer Center and Research Institute is unlike any other.

The House of Representatives June 19 passed a package of four appropriations bills for fiscal year 2020.

The FDA Oncology Center of Excellence announced a pilot program to help physicians get access to unapproved therapies for patients with cancer.

NCI and its advisors are stumped by a deep medical mystery: Why has the number of grant applications received by the institute grown by nearly 50% since 2013?

The mCODE initiative, developed by American Society of Clinical Oncology and its partners, aims to optimize electronic health records to answer research questions on drug efficacy and patient outcomes.

The American Society of Clinical Oncology published a set of common standards for cancer data elements via an initiative dubbed mCODE.

Our investigative story this week is an outgrowth of a correction.

Using a da Vinci robot for breast cancer surgery? Is it safe? Effective?

So, you've finished your copy of the Mueller Report and you long for another great read from the same publisher—the U.S. government.

The FDA Oncologic Drugs Advisory Committee May 14 voted 8-3 against approval of quizartinib for the treatment of adults with relapsed or refractory acute myeloid leukemia which is FLT3- ITD positive, as detected by an FDA-approved test.

When NCI renewed the Comprehensive Cancer Center designation for Rutgers Cancer Institute of New Jersey, it also acknowledged that the institution's catchment area now covers the entire state of New Jersey, having expanded from roughly three counties around its home location of New Brunswick.

Georgetown's Louis M. Weiner and Hackensack's Andrew L. Pecora started to discuss forming a consortium in 2011, roughly at the time when it became clear that conferencing and data transfer technologies were making it possible for cancer centers located hundreds of miles apart to operate in a coordinated manner.

NCI has funded a consortium uniting Georgetown Lombardi Cancer Center and John Theurer Cancer Center of Hackensack University Medical Center.

MD Anderson is the first institution to address the interrelated problems of theft of intellectual property, violation of ethics of NIH peer review, and researchers' failure to disclose foreign affiliations and sources of funding.